Streetbeat News

Earnings

SPRY

ARS Pharmaceuticals (NASDAQ:SPRY) reported Q2 losses of $(0.18) per share, missing the analyst consensus estimate of $(0.17) by 5.88 percent. The company reported $10.00 thousand in sales this quarter.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:36 pm

VIAV

Viavi Solutions has projected its Q1 adjusted EPS to be between $0.09 and $0.11, lower than the estimated $0.12. The company also expects its net revenue to be between $240M and $260M, which is less than the estimated $268.53M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:36 pm

PLSE

Pulse Biosciences (NASDAQ:PLSE) reported Q2 adjusted losses of $(0.19) per share, beating the analyst consensus estimate of $(0.22) by 13.64%. This represents a 50% decrease in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:34 pm

CETX

Cemtrex reported Q3 losses of $(1.29) per share, missing the analyst consensus estimate of $(0.34) by 279.41%. This is a 22.86% decrease over losses from the same period last year. However, the company's quarterly sales of $14.73 million beat the analyst consensus estimate of $14.45 million by 1.94%, marking an 8.06% increase over sales from the same period last year.

Portfolio Pulse from bharat@benzinga.com

August 10, 2023 | 8:34 pm

AKLI

Akili Interactive Labs has reaffirmed its fiscal year 2023 expense guidance in the range of $55 million to $60 million.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:33 pm

INDI

Indie Semiconductor (NASDAQ:INDI) reported Q2 sales of $52.10 million, beating the analyst consensus estimate of $52.01 million by 0.17 percent. This represents a 102.29 percent increase over sales of $25.75 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:33 pm

BTMD

Biote has revised its FY23 revenue forecast to $190M-$200M, which is lower than the previous estimate of $195.36M. The company attributes this to temporary inefficiencies from the realignment and expansion of sales geographies and evolving market dynamics. The company expects a slower growth pace in the second half of 2023.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 8:33 pm

RAIN

Rain Oncology reported Q2 losses of $(0.61) per share, missing the analyst consensus estimate of $(0.51) by 19.61%. This is a 7.58% increase over losses of $(0.66) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:33 pm

ARLO

Arlo Technologies has projected its Q3 adjusted EPS to be between $0.04 and $0.10, compared to the estimated $0.07. The company also expects its revenue to be between $122M and $132M, against the estimated $126.75M.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:32 pm

EVLV

Evolv Technologies reported better-than-expected Q2 financial results and raised its FY23 revenue guidance above estimates, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 8:32 pm